Trillium Asset Management LLC Has $9.96 Million Position in Merit Medical Systems, Inc. $MMSI

Trillium Asset Management LLC reduced its stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 4.7% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 106,519 shares of the medical instruments supplier’s stock after selling 5,238 shares during the quarter. Trillium Asset Management LLC’s holdings in Merit Medical Systems were worth $9,957,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Amundi grew its holdings in Merit Medical Systems by 2.2% during the first quarter. Amundi now owns 132,780 shares of the medical instruments supplier’s stock valued at $13,804,000 after purchasing an additional 2,847 shares during the period. Wellington Management Group LLP grew its holdings in Merit Medical Systems by 15.3% during the first quarter. Wellington Management Group LLP now owns 260,084 shares of the medical instruments supplier’s stock valued at $27,493,000 after purchasing an additional 34,448 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Merit Medical Systems by 119.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 367 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 200 shares during the period. Fred Alger Management LLC grew its holdings in Merit Medical Systems by 22.9% during the first quarter. Fred Alger Management LLC now owns 154,707 shares of the medical instruments supplier’s stock valued at $16,354,000 after purchasing an additional 28,793 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Merit Medical Systems by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,967 shares of the medical instruments supplier’s stock valued at $3,908,000 after purchasing an additional 1,436 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Insiders Place Their Bets

In related news, Director Lynne N. Ward sold 3,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $88.56, for a total transaction of $265,680.00. Following the completion of the sale, the director owned 12,809 shares of the company’s stock, valued at $1,134,365.04. This represents a 18.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 3.20% of the stock is owned by corporate insiders.

Merit Medical Systems Stock Up 1.3%

NASDAQ MMSI opened at $88.47 on Wednesday. The company has a current ratio of 4.09, a quick ratio of 2.66 and a debt-to-equity ratio of 0.49. Merit Medical Systems, Inc. has a 1-year low of $78.12 and a 1-year high of $111.45. The company has a 50 day moving average of $84.83 and a 200-day moving average of $89.15. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 44.91, a PEG ratio of 2.62 and a beta of 0.58.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.10. Merit Medical Systems had a net margin of 8.31% and a return on equity of 15.07%. The company had revenue of $384.20 million during the quarter, compared to the consensus estimate of $371.69 million. During the same period in the previous year, the business earned $0.86 earnings per share. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. Merit Medical Systems has set its FY 2025 guidance at 3.660-3.790 EPS. On average, equities research analysts expect that Merit Medical Systems, Inc. will post 3.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MMSI has been the subject of a number of analyst reports. Barrington Research boosted their price objective on shares of Merit Medical Systems from $103.00 to $106.00 and gave the company an “outperform” rating in a report on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $108.00 price objective on shares of Merit Medical Systems in a research report on Friday, October 31st. Robert W. Baird set a $103.00 price objective on Merit Medical Systems in a research report on Friday. Zacks Research upgraded Merit Medical Systems from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Finally, Piper Sandler reissued an “overweight” rating and issued a $109.00 price objective (up previously from $105.00) on shares of Merit Medical Systems in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $106.50.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.